10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

08/10/2023 32 min Temporada 1 Episodio 10

Ouvir "10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma"

Descargar episodio Ver en sitio original

Sinopse do Episódio

Discussão do artigo: "Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma" de Rodriguez‐Otero P, N Engl J Med 2023;388:1002-14
Apresentado por: Dr. Diego Luz
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dra. Thais Araujo, Dra. Fernanda Azevedo, Dr. Pedro Arruda e Dra. Roberta Szor.

Mais episódios do podcast TMO EPM / Hemato H9J

66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study 30/12/2025

65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma 05/11/2025

64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin 02/11/2025

63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT 01/09/2025

62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation 10/08/2025

61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study 04/08/2025

60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 27/07/2025

59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation 23/07/2025

58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 study 13/07/2025

57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults 06/07/2025

Ver todos los episodios